- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
This is most common urological condition and multiple sites of urinary tract are involved in this type of infection. my this PPT slide is helpful to all the student and faculty to increasing their knowledge about UTI.
Trichomoniasis
Causes of trichomoniasis
Infectious area
Symptoms
Risk factors
Diagnosis
Management
Trichomoniasis, or trich is a sexually transmitted infection (STI) caused by a tiny parasite called Trichomonas vaginalis (TV).
About 70% of women and men do not have symptoms when infected.
This is most common urological condition and multiple sites of urinary tract are involved in this type of infection. my this PPT slide is helpful to all the student and faculty to increasing their knowledge about UTI.
Trichomoniasis
Causes of trichomoniasis
Infectious area
Symptoms
Risk factors
Diagnosis
Management
Trichomoniasis, or trich is a sexually transmitted infection (STI) caused by a tiny parasite called Trichomonas vaginalis (TV).
About 70% of women and men do not have symptoms when infected.
Gonorrhea
is a sexually transmitted disease (STD) caused by a bacterium.
Gonorrhea can grow easily in the warm, moist areas of the reproductive
tract, including the cervix (opening to the womb), uterus (womb), and
fallopian tubes (egg canals) in women, and in the urethra (urine canal)
in women and men. The bacterium can also grow in the mouth, throat,
eyes, and anus.
People get gonorrhea by having sex with someone who has the disease.
“Having sex” means anal, vaginal, or oral sex. Gonorrhea can still be
transmitted via fluids even if a man does not ejaculate. Gonorrhea can
also be spread from an untreated mother to her baby during childbirth.
People who have had gonorrhea and have been treated may get infected
again if they have sexual contact with a person infected with
gonorrhea.
Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the poliovirus. In about 0.5 percent of cases there is muscle weakness resulting in an inability to move.
Two types of vaccine are used throughout the world to combat polio. Both types induce immunity to polio, efficiently blocking person-to-person transmission of wild poliovirus, thereby protecting both individual vaccine recipients and the wider community.
This ppt contains all information about epidemiology of Diptheria. It is useful for students of medical field learning preventive and social medicine, Swasthavritta (Ayurved), nursing and everyone who is interested in knowing about it.
Valour is a digital asset investment firm that allows traditional investors to identify and invest in a diversified
portfolio of digital assets across the decentralized finance, Web 3.0 and gaming sector. We capture the
upside in the explosive growth of the regulated Web 3.0 & future of gaming space via regulated equity
wrappers and a strategic partnership and ownership stake in SEBA Bank AG, a regulated crypto bank. We
are the only publicly traded company built to give investors direct exposure to these nascent markets.
Valour is a digital asset investment firm that allows traditional investors to identify and invest in a diversified
portfolio of digital assets across the decentralized finance, Web 3.0 and gaming sector. We capture the
upside in the explosive growth of the regulated Web 3.0 & future of gaming space via regulated equity
wrappers and a strategic partnership and ownership stake in SEBA Bank AG, a regulated crypto bank. We
are the only publicly traded company built to give investors direct exposure to these nascent markets.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Pathway Health is one of the largest providers of out-of-hospital pain management services in Canada. We own and operate nine community-based clinics across four provinces where our team of health professionals work together to help patients by using a variety of evidence-based approaches.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
We’re creating better everyday products that combine cutting-edge plant-based materials and the latest sustainable designs so you can look good AND feel good!
Hemptown Spring 2019 Investor PresentationHemptown USA
From the rich soils of Southern Oregon's Emerald Triangle, Hemptown USA is producing some of the finest cannabinoid products in the world.
Hemptown USA’s toolkit is a unique one. Combined with our vertically integrated business model we are in firmly positioned to capitalize on a global market expected to exceed $22 billion by 2020.
OKYO Pharma Limited (LSE: OKYO) operates as a life sciences and biotechnology company in the United Kingdom. Its development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM-8, a non-opiod analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.
Gonorrhea
is a sexually transmitted disease (STD) caused by a bacterium.
Gonorrhea can grow easily in the warm, moist areas of the reproductive
tract, including the cervix (opening to the womb), uterus (womb), and
fallopian tubes (egg canals) in women, and in the urethra (urine canal)
in women and men. The bacterium can also grow in the mouth, throat,
eyes, and anus.
People get gonorrhea by having sex with someone who has the disease.
“Having sex” means anal, vaginal, or oral sex. Gonorrhea can still be
transmitted via fluids even if a man does not ejaculate. Gonorrhea can
also be spread from an untreated mother to her baby during childbirth.
People who have had gonorrhea and have been treated may get infected
again if they have sexual contact with a person infected with
gonorrhea.
Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the poliovirus. In about 0.5 percent of cases there is muscle weakness resulting in an inability to move.
Two types of vaccine are used throughout the world to combat polio. Both types induce immunity to polio, efficiently blocking person-to-person transmission of wild poliovirus, thereby protecting both individual vaccine recipients and the wider community.
This ppt contains all information about epidemiology of Diptheria. It is useful for students of medical field learning preventive and social medicine, Swasthavritta (Ayurved), nursing and everyone who is interested in knowing about it.
Valour is a digital asset investment firm that allows traditional investors to identify and invest in a diversified
portfolio of digital assets across the decentralized finance, Web 3.0 and gaming sector. We capture the
upside in the explosive growth of the regulated Web 3.0 & future of gaming space via regulated equity
wrappers and a strategic partnership and ownership stake in SEBA Bank AG, a regulated crypto bank. We
are the only publicly traded company built to give investors direct exposure to these nascent markets.
Valour is a digital asset investment firm that allows traditional investors to identify and invest in a diversified
portfolio of digital assets across the decentralized finance, Web 3.0 and gaming sector. We capture the
upside in the explosive growth of the regulated Web 3.0 & future of gaming space via regulated equity
wrappers and a strategic partnership and ownership stake in SEBA Bank AG, a regulated crypto bank. We
are the only publicly traded company built to give investors direct exposure to these nascent markets.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Pathway Health is one of the largest providers of out-of-hospital pain management services in Canada. We own and operate nine community-based clinics across four provinces where our team of health professionals work together to help patients by using a variety of evidence-based approaches.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
We’re creating better everyday products that combine cutting-edge plant-based materials and the latest sustainable designs so you can look good AND feel good!
Hemptown Spring 2019 Investor PresentationHemptown USA
From the rich soils of Southern Oregon's Emerald Triangle, Hemptown USA is producing some of the finest cannabinoid products in the world.
Hemptown USA’s toolkit is a unique one. Combined with our vertically integrated business model we are in firmly positioned to capitalize on a global market expected to exceed $22 billion by 2020.
OKYO Pharma Limited (LSE: OKYO) operates as a life sciences and biotechnology company in the United Kingdom. Its development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM-8, a non-opiod analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Canadian Overseas Petroleum Limited: Investor Presentation - October 2022 CHF Investor Relations
COPL is an international oil and gas exploration, development and production
company actively pursuing opportunities in the United States with operations in
Converse County Wyoming, and in sub-Saharan Africa through its ShoreCan joint
venture company in Nigeria, and independently in other countries.
The Company’s Wyoming operations are one of the most environmentally responsible
with minimal gas flaring and methane emissions combined with electricity sourced
from a neighbouring wind farm to power production facilities.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
2. PROPRIETARY AND CONFIDENTIAL
DISCLAIMER
This confidential presentation (this “Presentation”) is for informational purposes only to assist interested parties who are either qualified institutional buyers or institutional accredited investors in making their own evaluation with respect to the proposed public offering of
INNO Holdings Inc. (the “Company”). The information contained herein does not purport to be all-inclusive and the Company and its affiliates make, and each hereby disclaims, any representation or warranty, express or implied, as to the reasonableness, accuracy,
completeness or reliability of the information contained in this Presentation. Viewers of this Presentation should make their own evaluation of the Company and of the relevance and accuracy of the information and should make such other investigations as they deem
necessary. None of the Company nor any of their respective affiliates, directors, officers, employees, advisers or representatives or the underwriters will be responsible or liable for any loss howsoever arising from these materials or any information presented or contained
in or derived from these materials. The information presented or contained in these materials is subject to change without notice and its accuracy, fairness or completeness is not guaranteed.
The information contained in this Presentation is highly confidential and may not be forwarded, published or distributed, directly or indirectly, to any other person (whether within or outside your organization or firm) for any purpose and may not be reproduced in any
manner whatsoever. Any forwarding, publication, distribution or reproduction of this presentation in whole or in part is unauthorized.
This Presentation contains forward-looking statements, including statements about the Company’s business and financial outlook, strategy and market opportunity, and other descriptions and information regarding the intent, belief, or current expectations of the Company
or its officers about the future. These statements can be recognized by the use of words such as “expects,” “plans,” “will,” “estimates,” “projects,”
“intends,” or words of similar meaning. These statements are forward-looking statements within the meaning of the U.S. securities laws. These forward-looking statements are made only, and are based on, estimates and information available to the Company, as of the
date of this Presentation, and are not guarantees of future performance. All statements other than statements of historical fact in this Presentation are forward-looking statements, including but not limited to, the Company’s goals and growth strategies; the Company’s
expectations regarding demand for and market acceptance of the Company’s brand and platforms; the Company’s future business development, results of operations and financial condition; the Company’s ability to establish manufacturing operations in the United States;
the we Company’s ability to maintain and improve the Company’s infrastructure necessary to operate the Company’s business; competition in the building/construction industry; the expected growth of, and trends in, the markets for the Company’s products and services in
the markets in which jurisdictions that we sell the Company’s products; the expected growth of, and trends in, the markets for the Company’s products and services in the markets in which jurisdictions that sell the Company’s products; the effect of supply chain issues on the
Company’s ability to manufacture and the Company’s ability and the ability of the Company’s distributors to distribute product; the development of a market for cold-formed steel framing product and the Company’s ability to market cold formed steel products; effects of
the COVID-19 pandemic and steps taken by governments to address the pandemic and the effect of the COVID-19 pandemic on the Company’s supply chain; government policies and regulations relating to the Company’s operations, including regulations relating to the
sale and distribution of the Company’s cold-formed steel products and those relating to manufacturing operations; the Company’s ability to develop and maintain effective disclosure controls and internal controls over financial reporting; the Company’s ability to use of
proceeds from its proposed initial public offering in the manner contemplated by the Company; the effect of any sales or the anticipation of sales by the selling stockholders upon the market price of the Company’s common stock; the Company’s ability to comply meet the
initial listing requirement on the Nasdaq Stock Market and the continued listing standards; the Company's ability to operate as a public company; the period of time for which its current liquidity will enable the Company to fund its operations; general economic and
business conditions; the volatility of the Company's operating results and financial condition and the price of its common stock; the Company's ability to attract and retain qualified senior management personnel and research and development staff; and assumptions
underlying or related to any of the foregoing and other risks detailed in the Company's filings with the Securities and Exchange Commission and available on its website at http://www.sec.gov.
These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure
you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.
In this Presentation, the Company rely on and refer to certain information and statistics regarding the markets and industries in which the Company competes. Such information are based on management’s estimates and/or obtained from third-party sources, including
reports by market research firms and company filings. While the Company believes such third-party information is reliable, there can be no assurances as to the accuracy or completeness of the indicated information. The Company has not independently verified the
accuracy or completeness of the information provided by the third-party sources.
This Presentation and any oral statements made in connection with this Presentation are not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy or a recommendation to purchase any security of the company or any of its affiliates, nor
shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sales would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus
meeting the requirements of Section 10 of the Securities Act or in reliance on an exemption from the registration requirements of the Securities Act. You should not construe the contents of this Presentation as legal, tax accounting, or investment advice or a
recommendation. You should consult your own counsel and tax and financial advisors as to the legal, financial, and related matters concerning the matters described herein, and by accepting this Presentation, you confirm that you are not replying upon the information
contained herein to make any decision. The distribution of the Presentation may also be restricted by law and persons into whose possession this Presentation comes should information themselves about and observe any such restrictions. The recipient acknowledges that it
is (a) aware that the United States securities laws prohibit any person who has material, non-public information concerning a company from purchasing or selling securities of such company or from communicating such information to any other person under circumstances
in which it is reasonably foreseeable that such person is likely to purchase or sell such securities (b) familiar with the Securities Exchange Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”), and that the
recipient will neither use, nor cause any third party to use, this Presentation or any information contained herein in contravention of the Exchange Act, including, without limitation, Rule 10b-5 thereunder.
THIS PRESENTATION IS BEING DISTRIBUTED TO SELECTED RECIPIENTS ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO , OR USE BY, ANY PERSON OR ENTITY IN ANY JURISDICTION OR COUNTRY WHERE SUCH DISTRIBUTION OR USE WOULD BE
CONTRARY TO APPLICABLE LAW OR REGULATION. AS OF THE DATE HEREOF, NONE OF THE INFORMATION CONTAINED HEREIN HAS BEEN FILED WITH THE SEC, ANY SECURITIES ADMINISTRATOR UNDER ANY SECURITIES LAWS OF ANY U.S OR NON-U.S
JURISDICTION, OR ANY OTHER U.S OR NON-U.S. GOVERNMENTAL OR SELF-REGULATORY AUTHORITY. NO SUCH GOVERNMENTAL OR SELF-REGULATORY AUTHORITY WILL PASS ON THE MERITS OF ANY OFFERING OF INTERESTS IN CONNECTION TO THE
COMPANY OR THE ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO TE CONTRARY IS UNLAWFUL.
3. PROPRIETARY AND CONFIDENTIAL
Issuer: INNO HOLDINGS INC.
Proposed Listing/Symbol: NASDAQ Capital Market / INHD
Offering Type: Initial Public Offering
Securities Offered: Class A Common Stock
Offering Size: ~ $9MM-$11MM
Price Range: ~ $4.00-$5.00
Use of Proceeds: • 20% attributed to increase marketing capabilities
• 20% attributed to increase production capacity
• 20% attributed to expand research and development and evaluate
strategic opportunities
• 40% attributed to working capital and general corporate purposes
Expected Pricing Date: TBD
Underwriter: AC Sunshine Securities LLC
OFFERING SUMMARY
4. PROPRIETARY AND CONFIDENTIAL
OVERVIEW
$270.39
BTotal Addressable Markets1
11
%
Building and Construction Materials
Share of Global CO2 Emissions4
5
Patents Pending2
$15-
20M
Customer Backlog3
Notes:
1. According to several studies cited in S1 Filing
2. Patents Pending as of June 30, 2023
3. Based on signed customer contracts as of June 30, 2023
4. Global Status Report 2018, Global Alliance for Buildings and Construction & International Energy Agency
5. PROPRIETARY AND CONFIDENTIAL
“Revolutionize the construction industry through innovative technology, significantly
reducing both costs and environmental impact while maximizing shareholder value. Our
commitment lies in delivering durable, resilient structures that ensure quality,
affordability, and sustainability for all.”
Our Mission
6. PROPRIETARY AND CONFIDENTIAL
LEADERSHIP TEAM
CEO
Dekui (D.K) Liu
CFO
Tianwei (Solomon) Li, MBA
COO
Dr. Li (Alice) Gong, Ph.D., MSBA
Mr. Liu has over 10 years of ground-up experience within the real estate development industry in the United States. Three
generations of his family have been engaged in the industrial industry. Having grown up in the entrepreneurial environment,
he took his family’s inherited interest in machinery. Practical experience in machinery made him proficient in mechanical
principles, electronics principles, and hydraulic transmission principles. He is the author of five mechanical-related pending
patents in the United States.
Mr. Li is a highly accomplished finance professional with a diverse background in financial management, venture capital, and
financial advisory. He has held leadership positions at prestigious institutions, demonstrating exceptional leadership skills and
strategic decision-making abilities. Mr. Li is committed to delivering exceptional financial solutions and building long-lasting
client relationships.
Dr. Gong has over 10 years of experience in the field of financial analysis. With INNO since its inception, Dr. Gong leverages
her deep understanding of economics to analyze current market trends and develop creative ways to drive growth. From the
outset, Dr. Gong has been critical in driving revenue generation, controlling costs, managing operations, budgeting, and
developing marketing strategies.
7. PROPRIETARY AND CONFIDENTIAL
The OPPORTUNITY
We manufacture components in-house utilizing cutting-edge
methodologies and eco-friendly materials to ensure maximum quality
and sustainability.
• TURNKEY
CONSTRUCTION
REDUCES OVERALL
CONSTRUCTION COST
• ON-SCHEDULE DELIVERY
• REDUCED LABOR
REQUIREMENTS
• ZERO PROJECT DELAYS
ADVANCED OFF-SITE
FABRICATION WITH
STRUCTURAL
STEEL FRAMING
8. PROPRIETARY AND CONFIDENTIAL
• Highly Sustainable **
OPPORTUNITY
SHIFT
THE INNO
WAY
• Predictable Outcomes
• Fast, Reliable Construction
• High Quality Control
• Efficient
• Low waste of materials
• Minimal Rework
• Predictability builds precision
pricing
* Building and construction materials account for ~11% of global
CO2 emissions (Global Status Report 2018, Global Alliance for
Buildings and Construction & International Energy Agency1)
** North American cold rolled steel is often at least partly derived
from steel scraps or recycled steel in energy-efficient electric arc
furnaces; our production scrap is recycled; our steel products are
both long-lasting and recyclable
Compared to the traditional wood framing
Variable Outcomes
Mix of unskilled / skilled labor
Poor quality control
Inefficient
High waste of materials
Environmentally unfriendly*
Excessive rework
Variability drives mark-ups
9. PROPRIETARY AND CONFIDENTIAL
$270B + Existing Global Market Opportunity
U.S. Framing + U.S. Prefabricated Home Manufacturing
$33B
in 2023
$130B
in 2023 $106B
in 2023
Global
Light-Gauge
Steel Framing1
Global Offsite
Construction2
Global Prefab
Home
Manufacturing3
Sources:
1. Light Gauge Steel Framing Market Size Worth $42.8 billion by 2027 (kbvresearch.com)
2. https://www.alliedmarketresearch.com/offsite-construction-market-A12504
3. https://www.ibisworld.com/industry-statistics/market-size/prefabricated-home-manufacturing-united-states/
10. PROPRIETARY AND CONFIDENTIAL
$40B + Existing US Market Opportunity
U.S. Framing + U.S. Prefabricated Home Manufacturing
$6B
in 2023
$25B
in 2023
$9B
in 2023
U.S.
Light-Gauge
Steel Framing1
U.S. Traditional
Wood Framing2
U.S. Prefab
Home
Manufacturing3
Sources:
1. Light Gauge Steel Framing Market Size Worth $42.8 billion by 2027 (kbvresearch.com)
2. https://www.ibisworld.com/industry-statistics/market-size/wood-framing-united-states/,
3. https://www.ibisworld.com/industry-statistics/market-size/prefabricated-home-manufacturing-united-states/
11. PROPRIETARY AND CONFIDENTIAL
Intelligent Metal Framing
Studs
Castor Cube
Luxury Prefab Home
Mobile Factory
Our Four Initial
Products
101 Series
Replicable Apartment/Condo
Product
12. PROPRIETARY AND CONFIDENTIAL
INNO METAL STUDS
(IMS)
CASTOR BUILDING TECHNOLOGIES
(CBT)
INNO RESEARCH INSTITUTE
(IRI)
INNO HOLDINGS
Three Established Subsidiaries
14. PROPRIETARY AND CONFIDENTIAL
CUSTOM
FORMED
We leverage
proprietary steel
forming
equipment for
rapid, low-cost
production of steel
framing
FACTORY
MADE
~70% of the
framing work is
completed in our
factory1
FASTER
Custom framing
members can speed
on-site framing and
reduce labor
costs by 50% or
more1; no need for
highly skilled labor
REDUCED
WASTE
Factory-built studs
can virtually
eliminate on-site
framing waste1
LIGHT GUAGE STEEL
STUDS & PANELS
Source: 1. Based on INNO Holdings observations and estimates
15. PROPRIETARY AND CONFIDENTIAL
IMS Framing is Superior to Wood
Infinitely recyclable
Virtually no waste
Rapid on-site construction
Non-combustible
Termite, rodent, and mildew resistant
Durable
Flood resistant
Dimensionally stable
3.5x stronger than wood
Clean interior air; no off-gassing
Deforestation; loss of carbon sink
10-20%+ construction waste
Long construction times
Flammable
Susceptible to mold and infestations
Can degrade or rot over time
Susceptible to water damage
Warped, uneven, imprecise
Weaker than steel
Potential chemical/mold air contaminants
INNO METAL STUD WOOD
Lower insurance premiums Higher insurance premiums
17. PROPRIETARY AND CONFIDENTIAL
Village 101
01
02
03
04
Innovative Materials
Reduce Construction
Costs
Prefab Steel Structures featuring Innovative Cladding Material will
save construction cost.
Product Pipeline
The Construction
of Community
By meeting the requirements in the designated parcel, we can eliminate the
project design process, allowing us to quicky replicate prototypes, saving
time and money.
Our pipeline includes various apartment product options with different unit
sizes, ranging from 15 to 150 units.
After the erection of Village 101, it can drive growth to surrounding industries,
services, and employment opportunities.
A prototype apartment community
that can be replicated nationwide
Standardized Plan Set
Residents of this development gain awareness of other INNO product
lines via vertical integration of the INNO brand.
18. PROPRIETARY AND CONFIDENTIAL
Business
Chart
Flexible
Manufacturing
Primary manufacturing site is in
Texas, mobile
manufacturing can be
situated at any construction
site for rapid production
High Quality
Products meet the highest
quality standards: INNO
received ICC-ES: ESR-4641
certification in July, 2020, and
three ISO certifications in
October, 2020
National Reach
We supply metal framing
components throughout the U.S.
100%
MADE IN USA
Materials are locally sourced
and products are 100%
made in the U.S.
Existing Capacity
Can Support
Substantial
Revenue Growth
20. PROPRIETARY AND CONFIDENTIAL
Durable
Designed to resist
earthquakes,
hurricane force winds,
and pests
Proprietary
to INNO
Leverages metal framing
and our patent-pending
aluminum honeycomb panels
Fast &
Predictable
Completely premanufactured
at our facilities, with initial
projected capacity of one
home per day
Highly
Efficient
Low maintenance,
efficient, affordable,
modern prefab home
Portable
743 sqft.; fits on a trailer
for easy transportation
and installation
Modern Prefab Homes
21. PROPRIETARY AND CONFIDENTIAL
Structure Material Light Gauge Steel and Iron Wood chips and Synthetic
Materials
Wood
Wall Material Patent-Pending Honeycomb Aluminum Panels
Soundproof and Rust Resistant
Sheet Metal Plywood and Sheetrock
Roof Material Galvanized Aluminum
Gutter Included
Metal
No Gutter Included
Standard Shingles
20-25 Year Lifespan
MEP & HVAC MEP & HVAC Included MEP Included
HVAC Limited
MEP & HVAC Included
Target Market Middle and High-Budget Customers
Pursuing Quality of Life Without Sacrifice
Lower and Middle-Budget
Customers
Focus on Speed of Assembly
Lowest-Budget Customers and
Trailer Parks
Market Cap/Valuation $30 Million $3 Billion $1.7 Billion*
(*Acquired by Berkshire Hathaway in 2003)
Pre-Fabricated Home Competitor Analysis
24. PROPRIETARY AND CONFIDENTIAL
INNO
RESEARCH
INSTITUTE
VALUABLE IP
Our research efforts are perhaps our most significant
competitive advantage; we have a pipeline of
over 100 potential patentable innovations
CATEGORY LEADER
Current research includes the development of high-
strength, large-span trusses and other metal
framing innovations
COMMERCIAL FOCUS
Our product development focuses on products with
strong potential for commercial success
ENGINEERING SERVICES
IRI provides engineering services and consulting for
our customers
26. PROPRIETARY AND CONFIDENTIAL
INNO has achieved significant growth despite the challenging economic
conditions brought on by the Covid-19 pandemic. Despite the adverse effects
of these events, INNO has continued to flourish and exhibit robust growth.
This speaks to the resilience and adaptability of the company, which has
managed to weather the storm and emerge even stronger.
ANNUAL REVENUE ($M)
50%
ANNUAL RENENUE
GROWTH RATE
ANNUAL REVENUE ($M)
270%
ANNUAL CUSTOMER
GROWTH RATE
*includes 55% repeat customers Y/Y
27. PROPRIETARY AND CONFIDENTIAL
$15-20
Million
• Our backlog as of June
30, 2023 is $15-20mm.
• Our backlog consists of
all remaining payments
related to our signed
customer contracts.
• We expect revenue from
these contracts to be
realized within 24
months.
28. PROPRIETARY AND CONFIDENTIAL
1
2
3
4
Investing to Support
Growth
Expanding R&D, Marketing,
Sales
Existing Capacity Can
Support Substantial
Revenue Growth
Large Project Pipeline
Financial Metrics
F2021 F2022
Revenue
(in Thousands)
$3,004 $4,503
Gross Margin 31.1% 24.4%
Net Income
(in Thousands)
($106) ($1,009)
F2022 Q1-Q3 F2023 Q1-Q3
Revenue
(in Thousands)
$3,532 $502
Gross Margin 36.2% 5.8%
Net Income
(in Thousands)
($509) ($2,864)
Notes: The decline in revenue primarily resulted from a decrease in customer construction activity, a decline in the number
of customers, and a decline in the average size of projects.
29. PROPRIETARY AND CONFIDENTIAL
Planned Levers for Continued Growth
Large and Growing
Project Pipeline
Expanded Sales and
Marketing Efforts
Continue Delivering
Innovative Products
Launch of Castor Cube Pre-
fab Homes in Late-2023
Increased focus on replicable
apartments, light commercial projects,
and multi-unit home developments
We anticipate strong demand, with the
potential for multi-unit sales to land
developers
We plan to invest in sales and
marketing to educate customers about
the benefits of our products
We plan to invest in the INNO
Research Institute to develop new
products that deliver high value for our
customers